We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

17 Jun 2026 - 19 Jun 2026
25 Jun 2026 - 27 Jun 2026
08 Jul 2026 - 10 Jul 2026

Bayer to Acquire Visible Genetics, Inc.

By HospiMedica staff writers
Posted on 12 Aug 2002
In a move that will expand its portfolio of molecular diagnostic tests, an agreement has been announced by Bayer Corp., Diagnostics Division (Tarrytown, NY), to acquire Visible Genetics Inc.(VGI, Toronto, Canada) in a cash deal valued at US$61.4 million.

As part of the transaction, Bayer Diagnostics will acquire the Trugene HIV-1 Genotyping Assay, the only HIV sequencing resistance test available in the United States that is approved by the US Food and Drug Administration (FDA). More...
Combined with Bayer's Versant HIV and hepatitis C virus (HCV) viral nucleic acid tests, these will enable Bayer to have a leading position in the nucleic acid diagnostic (NAD) segment of the professional laboratory market. The acquisition will also include all VGI sequencing assays, such as hepatitis assays, currently in development.

"This acquisition is another milestone in our ongoing strategy to expand our infection disease portfolio that began with our acquisition of Chiron Diagnostics in 1998,” said Rolf Classon, president of Bayer Business Group Diagnostics. "It also supports our strategy to bring to market molecular diagnostic tests that assist the physician in the diagnosis and monitoring of disease and treatment regimens.”





Related Links:
Bayer Diagnostics
Visible Genetics

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
12-Channel ECG
CM1200B
Wound Irrigation Solution
Prontosan®
Multi-Chamber Washer-Disinfector
WD 390
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Coredio’s CPSE is a a software-as-a-medical-device platform designed for use with consumer smartwatches and standard blood pressure cuffs in clinical and home settings under physician supervision (Photo courtesy of Coredio)

AI Platform Supports Noninvasive Remote Hemodynamic Monitoring in Heart Failure

Heart failure remains a leading cause of hospitalization in adults over 65, affecting more than 6.7 million people in the U.S. Clinicians often lose visibility into hemodynamic deterioration once patients... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.